Affinivax Announces $226 Million Series C Financing to Advance Its Pipeline of Novel MAPS™ Vaccines Targeting Infectious Diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines ...
